News Releases

Nautilus Biotechnology Reports Third Quarter 2026 Financial Results

SEATTLE, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2026. Third Quarter 2026 Business Highlights Published a

Nautilus to Measure Proteoforms Driving Alzheimer’s Disease and Cancer in ARPA-H-Funded SEEDS Consortium

Nautilus expects to receive up to $6 million to bring its Voyager™ Platform to a multidisciplinary team integrating protein science, AI, and computational modeling to develop new diagnostics and therapeutics SEATTLE, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc.

Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026

SEATTLE, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter 2026 before market open on Tuesday, October 27, 2026.

Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms

First large-scale, single-molecule analysis of the tau proteoform landscape reveals unique disease-associated modifications, a new source of potential biomarkers and drug targets, and a method Nautilus is now extending across disease areas Key takeaways: Going beyond measurement of bulk tau to

Nautilus Biotechnology Reports Second Quarter 2026 Financial Results

SEATTLE, July 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Business Highlights Recognized first revenue in

Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026

SEATTLE, July 08, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the second quarter 2026 before market open on Tuesday, July 28, 2026.

Nautilus Biotechnology Reports First Quarter 2026 Financial Results

SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Business Highlights Initiated our Iterative

Nautilus Biotechnology to Announce First Quarter 2026 Financial Results on April 28, 2026

SEATTLE, April 09, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the first quarter 2026 before market open on Tuesday, April 28, 2026.

Nautilus Biotechnology to Participate in the Investor Summit Group Virtual Conference

SEATTLE, March 24, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Investor Summit Group Virtual Conference.

Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform

• Baylor selects the Nautilus Voyager™ Platform, now available through Early Access Program, for development of a first-in-class computational multi-omics toolkit • NIH-funded project leverages collaborators’ expertise in single-molecule proteomics and protein isoform quantification to advance